Halozyme Therapeutics, Inc.

Halozyme Therapeutics is a U.S. biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships. The company was founded in 1998 and went public in 2004.